Most Recent
Aristocrat has fended off the Commissioner of Patents' challenge to a finding that its Lightning Link poker machine is capable of being patented, with the High Court declining to weigh in on the patent for a second time.
Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno's generic version of schizophrenia drug Invega Sustenna.
The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
Law firm Gillis Delaney has defeated a bid for third-party costs by a warehouse management software company that was named in an intellectual property dispute, with a judge rejecting claims the firm was not authorised to act and acted unreasonably.
Isuzu has lost an appeal bid to shut down a lawsuit by car alarm company Directed Electronics over alleged trade secrets theft, after an earlier case left it with a $169 million damages bill.
A judge has ordered tech company Vehicle Management Systems to hurry up and choose between damages or an account of profits in its IP dispute with the city of Melbourne over a sensor-based system for timing parked vehicles.
A patent holding company is challenging the dismissal of its infringement case over Apple's Touch ID and Face ID technology.
Apple has defeated a claim by an Australian non-practicing entity that its patents for a remote entry system were infringed by the tech company’s Touch ID and Face ID technology.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen's bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.